FDA due to rule by April 17, 2018

The U.S. Food and Drug Administration has set the calendar for its review of KRN23/burosumab, the promising new treatment for XLH, and granted "priority review" status that will expedite the process. A decision is due from the FDA by April 17, 2018.

You can read the press release here:http://ir.ultragenyx.com/releasedetail.cfm?ReleaseID=1043322